Tempest Therapeutics TPST-2003 CAR-T Shows Promise for Multiple Myeloma at ISCT 2026

Key Takeaways

• TPST-2003 dual-targeting CD19/BCMA CAR-T therapy shows clinical benefit in relapsed/refractory multiple myeloma patients
• Data supports the parallel-structure dual-targeting CAR architecture’s potential to improve patient outcomes
• Results demonstrate particular promise for patients with challenging extramedullary disease

---

Tempest Therapeutics, Inc. (Nasdaq: TPST) announced it will present encouraging clinical data for its investigational dual-targeting CAR-T therapy TPST-2003 at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.

Clinical Data Highlights

The presentation will showcase results from multiple clinical studies evaluating TPST-2003, a novel CAR-T therapy that simultaneously targets both CD19 and BCMA antigens in patients with relapsed or refractory multiple myeloma.

The data demonstrates clinical benefit from Tempest’s parallel-structure dual-targeting CAR architecture, representing a significant advancement in CAR-T cell therapy design. Unlike traditional single-target approaches, this dual-targeting strategy aims to overcome common resistance mechanisms that limit the effectiveness of current multiple myeloma treatments.

Addressing Extramedullary Disease

Particularly noteworthy are the results showing TPST-2003’s potential effectiveness against extramedullary disease, a challenging form of multiple myeloma that occurs outside the bone marrow. This condition is notoriously difficult to treat and often indicates a more aggressive disease course.

Market Context

Multiple myeloma remains the second most common blood cancer, with approximately 35,000 new cases diagnosed annually in the United States. Despite advances in treatment, most patients eventually develop resistance to existing therapies, creating substantial unmet medical need.

The dual-targeting approach represents a promising strategy to address treatment resistance by simultaneously attacking two different pathways cancer cells use for survival and growth.

Company Background

Based in Brisbane, California, Tempest Therapeutics focuses on developing innovative cancer immunotherapies. The company’s CAR-T platform represents a key component of its oncology pipeline, with TPST-2003 serving as the lead candidate in this program.

The ISCT presentation will provide the medical community with updated efficacy and safety data that could influence future development strategies for dual-targeting CAR-T therapies in hematologic malignancies.

---

Frequently Asked Questions

What makes TPST-2003 different from other CAR-T therapies?

TPST-2003 uses a parallel-structure dual-targeting approach that simultaneously targets both CD19 and BCMA antigens, potentially overcoming resistance mechanisms that limit single-target CAR-T therapies.

When will TPST-2003 be available to patients?

TPST-2003 is currently in clinical trials. The timeline for potential approval will depend on ongoing study results and regulatory review processes, which typically take several years.

Who would be eligible for TPST-2003 treatment?

Based on current studies, TPST-2003 is being evaluated for patients with relapsed or refractory multiple myeloma, particularly those with extramedullary disease who have limited treatment options.